A Phase 1/2 interventional study of Bendamustine and Obinutuzumab in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 62 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.
Among the 253 studies testing rituximab in Lymphoma, this one is the 21st largest by enrollment of the 237 interventional ones that give a count, is one of 4 that started in 2014, is one of 24 in phase 1/2, and was the 227th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:
Gottfried von Keudell, MD PhD · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Portugal, Spain
Ages 18+
Second Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Christine Ryan · Sites in United States
Ages 18+
Christian Buske · Sites in Germany, Greece
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
253 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 184 · Phase 3 28
First in 1995; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 44 across the 237 interventional studies. Of the 212 that completed or were terminated, 102 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 253 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Lymphoma by Hoffmann-La Roche: 1 open now, 3 under way, 1 of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2014, is one of 4 in phase 1/2, and was the 10th registered.
Hoffmann-La Roche’s Lymphoma studies by the year they started, since 2002.
3 of the studies testing rituximab in Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06573645Phase 3Xia YiA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | 2027-01-12 |
| NCT05495464M.D. Anderson Cancer CenterA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | 2027-03-31 |
| NCT06557330Fox Chase Cancer CenterMRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | 2027-09-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 253 studies testing rituximab in Lymphoma, from their registry updates:
Among Hoffmann-La Roche’s 17 in Lymphoma:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18 weeks for participants with DLBCL and 24 weeks for participants with FL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab
Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
Drug: Bendamustine · Drug: Rituximab
Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab
Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
Drug: Bendamustine · Drug: Rituximab
Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab
Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab
Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)
In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
Drug: Bendamustine · Drug: Rituximab · Drug: Polatuzumab vedotin (Lyophilized)
In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
Drug: Bendamustine · Drug: Rituximab · Drug: Polatuzumab vedotin (Lyophilized)
Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Also known as: Treanda; Ribomustin; Levact
Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Also known as: GA101; Gazyva; Gazyvaro
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Also known as: DCDS4501A
Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Also known as: Rituxan; MabThera
Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
Also known as: DCDS4501S
Phase Ib: Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).
Time frame: From the study start up to the end of the study (up to approximately 84 months)
Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
Time frame: From Month 37 to Month 84 (up to approximately 47 months)
Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin
The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
Time frame: Baseline up to approximately Month 24
Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
Time frame: Baseline up to approximately Month 24
Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)
The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
Time frame: From Month 37 to Month 84 (up to approximately 47 months)
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)
CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
Time frame: 6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)
Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms\*day per milliliters.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks
Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Phase II: Percentage of Participants With AEs
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
Time frame: From the study start up to the end of the study (up to approximately 84 months)
Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin
The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
Time frame: Baseline to approximately Month 24
Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
Time frame: Baseline to approximately Month 24
Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator
BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
Time frame: Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)
DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC
BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
Time frame: Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)
DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)
DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)
DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator
PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)
DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC
PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)
Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately\>liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator
BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
Time frame: Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])
Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC
BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
Time frame: Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])
Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])
Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])
Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator
PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])
Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC
PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])
Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator
EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.
Time frame: From Month 37 to Month 84 (up to approximately 47 months)
Phase II NF Cohorts: Overall Survival (OS)
OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.
Time frame: From Month 37 to Month 84 (up to approximately 47 months)
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)
Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).
Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)
Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
Time frame: Cycle 1 Day 2: pre-dose and 30 minutes (min) post dose; Cycle 1 Days 8 and 15; Cycle 2 and 4 Day 1: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
Time frame: Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose
Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
Time frame: Cycle 1 Days 2: pre-dose & 30 min post dose; Cycle 1 Days 8 & 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose & 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 & 24; study treatment completion visit (up to approx. 84 months)
Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab
PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
Time frame: Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose
Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
Time frame: Cycle 1 Day 2: pre-dose and 30 min post dose, Cycle 1 Days 8 and 15; Cycles 2 and 4: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
Time frame: Cycle 1 Day 2: post dose; Cycle 1 and 3 Day 8 and 15; Cycle 2, 3 and 4 Day 1: pre-dose and post dose
Plasma Concentration of Bendamustine
Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).
Time frame: Cycle 1 Day 2: pre-dose, 5 min, 1 hour (h); 2h, 3h and 4h post dose
Serum Concentration of Rituximab
Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).
Time frame: Cycle 1 Days 1: pre-dose and 30 min post dose; Cycle 2 and 4 Day 1: pre-dose; unscheduled visits: pre-dose and 30 min post dose (up to approximately 84 months)
Serum Concentration of Obinutuzumab
Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
Time frame: Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.
Time frame: Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: Cmax of Bendamustine and Rituximab in Arms B and D
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F
PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.
Time frame: Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day\*micrograms per milliliter \[day\*ug/mL\]).
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks
Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: CL of Bendamustine and Rituximab in Arms B and D
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: Vss of Bendamustine and Rituximab in Arms B and D
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.
Time frame: Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)
A total of 331 participants with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B cell lymphoma (DLBCL) were enrolled in this study at 56 investigative sites in the following countries: Australia, Canada, Czech Republic, France, Germany, Hungary, Italy, Korea, the Netherlands, Spain, Turkey, United Kingdom, and the United States from 15 October 2014 to 21 October 2021.
| Milestone | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 39 | 41 | 40 | 40 | 20 | 21 | 106 |
| Safety population | 6 | 6 | 6 | 6 | 38 | 41 | 39 | 39 | 20 | 20 | 106 |
| Completed | 4 | 4 | 2 | 1 | 20 | 22 | 6 | 2 | 16 | 0 | 30 |
| Not completed | 2 | 2 | 4 | 5 | 19 | 19 | 34 | 38 | 4 | 21 | 76 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 2 | 2 | 2 | 4 | 15 | 11 | 26 | 30 | 2 | 18 | 65 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Not treated/per sponsor participant could not continue/pathology showed transformation: cycle 1day 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 | 0 | 6 | 6 | 6 | 1 | 1 | 10 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).
| percentage of participants | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL |
|---|---|---|---|---|
| Phase Ib: Percentage of Participants With Adverse Events (AEs) | 100 | 100 | 100 | 100 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs | 99.1 |
The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
| percentage of participants | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL |
|---|---|---|
| Baseline Prevalence of ADAs | 50.0 | 33.3 |
| Post-Baseline Incidence of ADAs | 0 | 33.3 |
The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
| percentage of participants | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL |
|---|---|---|
| Baseline Prevalence of ADAs to Polatuzumab vedotin | 0 | 0 |
| Post-Baseline Incidence of ADAs to Polatuzumab vedotin | 0 | 0 |
| Baseline Prevalence of ADAs to Obinutuzumab | 0 | 0 |
| Post-Baseline Incidence of ADA to Obinutuzumab | 0 | 0 |
The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | Arm H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|
| Baseline Prevalence of ADAs to Polatuzumab | 0.0 | 1.6 |
| Post-Baseline Incidence of ADAs to Polatuzumab | 2.6 | 5.0 |
CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|
| Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC) | 69.2 (52.43 to 82.98) | 63.4 (46.94 to 77.88) | 42.5 (27.04 to 59.11) | 17.5 (7.34 to 32.78) | 39.6 (30.25 to 49.59) |
CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC | 42.2 (29.94 to 55.18) |
Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms\*day per milliliters.
| ng*day/mL | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| acMMAE | 2880 ± 0.15 |
| MMAE | 21.6 ± 45 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| nanograms per milliliters (ng/mL) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| acMMAE | 724 ± 10 |
| MMAE | 2.01 ± 38 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)
No measurements were reported for this outcome.
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With AEs | 100 | 100 | 100 | 97.4 | 100 | 100 | 99.1 |
The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL |
|---|---|---|
| Baseline Prevalence of ADAs | 0 | 0 |
| Post-Baseline Incidence of ADAs | 7.9 | 2.9 |
The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|
| Baseline Prevalence of ADAs to Polatuzumab | 0 | 0 |
| Post-Baseline Incidence of ADAs to Polatuzumab | 5.3 | 5.6 |
| Baseline Prevalence of ADAs to Obinutuzumab | 0 | 0 |
| Post-Baseline Incidence of ADAs to Obinutuzumab | 0 | 0 |
CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator | 64.1 (47.18 to 78.80) | 63.4 (46.94 to 77.88) | 42.5 (27.04 to 59.11) | 15.0 (5.71 to 29.84) | 65.0 (40.78 to 84.61) | 33.3 (14.59 to 56.97) | 36.8 (27.63 to 46.71) |
CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G (Phase II Expansion): Pola+BR in DLBCL |
|---|---|---|---|
| Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC | 65.0 (40.78 to 84.61) | 33.3 (14.59 to 56.97) | 35.7 (21.55 to 51.97) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator | 79.5 (63.54 to 90.70) | 80.5 (63.13 to 91.18) | 47.5 (31.51 to 63.87) | 17.5 (7.34 to 32.78) | 85.0 (62.11 to 96.79) | 33.3 (14.59 to 56.97) | 42.5 (32.91 to 52.43) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC | 76.9 (60.67 to 88.87) | 73.2 (57.06 to 85.78) | 42.5 (27.04 to 59.11) | 17.5 (7.34 to 32.78) | 85.0 (62.11 to 96.79) | 38.1 (18.11 to 61.56) | 43.4 (33.80 to 53.37) |
CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator | 46.2 (30.09 to 62.82) | 19.5 (8.82 to 34.87) | 20.0 (9.05 to 35.65) | 5.0 (0.61 to 16.92) | 20.0 (5.73 to 43.66) | 14.3 (3.05 to 36.34) | 14.2 (8.14 to 22.26) |
CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC | 41.0 (25.57 to 57.90) | 36.6 (22.12 to 53.06) | 22.5 (10.84 to 38.45) | 2.5 (0.06 to 13.16) | 50.0 (27.20 to 72.80) | 23.8 (8.22 to 47.17) | 17.9 (11.15 to 26.57) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator | 79.5 (63.54 to 90.70) | 75.6 (59.70 to 87.64) | 45.0 (29.26 to 61.51) | 15.0 (5.71 to 29.84) | 80.0 (56.34 to 94.27) | 33.3 (14.59 to 56.97) | 42.5 (32.91 to 52.43) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC | 74.4 (57.87 to 86.96) | 80.5 (65.13 to 91.18) | 40.0 (24.86 to 56.67) | 15.0 (5.71 to 29.84) | 80.0 (56.34 to 94.27) | 38.1 (18.11 to 61.56) | 41.5 (32.02 to 51.49) |
BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
| percentage of participants | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|
| Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator | 89.7 (75.78 to 97.13) | 90.2 (76.87 to 97.28) | 70.0 (53.47 to 83.44) | 32.5 (18.57 to 49.13) | 90.0 (68.30 to 98.77) | 52.4 (29.78 to 74.29) | 62.3 (52.33 to 71.50) |
BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
| percentage of participants | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|
| DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC | 62.5 (45.80 to 77.27) | 25.0 (12.69 to 41.20) | 42.9 (21.82 to 65.98) | 57.5 (47.57 to 67.09) |
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
| months | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|
| DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator | 12.665 (5.782 to 27.926) | 4.074 (2.563 to 12.682) | 16.099 (2.825 to 27.860) | 11.335 (6.242 to 16.197) |
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
| months | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|
| DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC | 10.908 (5.684 to 40.674) | 10.645 (3.975 to 19.647) | 25.758 (9.692 to 46.752) | 13.437 (8.641 to 20.041) |
PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
| months | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|
| DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator | 7.491 (4.928 to 16.953) | 2.037 (1.544 to 3.713) | 5.125 (2.103 to 18.234) | 5.881 (4.764 to 7.524) |
PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
| months | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|
| DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC | 9.248 (6.045 to 13.930) | 3.713 (2.070 to 4.534) | 5.848 (2.103 to 11.893) | 6.965 (5.092 to 9.823) |
CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator | 36.8 (27.63 to 46.71) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately\>liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
| percentage of participants | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator | 42.5 (32.91 to 52.43) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
| percentage of participants | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC | 43.4 (33.80 to 53.37) |
BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
| percentage of participants | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator | 62.3 (52.33 to 71.50) |
BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
| percentage of participants | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC | 57.5 (47.57 to 67.09) |
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
| months | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator | 11.335 (6.242 to 16.197) |
DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
| months | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC | 13.437 (8.641 to 20.041) |
PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
| months | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator | 5.881 (4.764 to 7.524) |
PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
| months | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC | 6.965 (5.092 to 9.823) |
EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.
| months | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator | 5.092 (4.402 to 6.867) |
OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.
| months | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Phase II NF Cohorts: Overall Survival (OS) | 12.320 (8.279 to 16.986) |
CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
| percentage of participants | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC | 35.7 (21.55 to 51.97) |
CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.
| percentage of participants | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator | 9.5 (2.66 to 22.62) |
CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.
| percentage of participants | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC | 14.3 (5.43 to 28.54) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).
| percentage of participants | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator | 38.1 (23.57 to 54.36) |
OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).
| percentage of participants | Arm G (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC | 33.3 (19.57 to 49.55) |
PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
| ng/mL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2: Pre-dose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 2: 30 min Post Dose | 654 ± 29.3 | 617 ± 26.2 | 719 ± 26.7 | 718 ± 14.2 | 492 ± 241.6 | 643 ± 24.7 | 453 ± 682.8 | 472 ± 617.2 |
| Cycle 1 Day 8 | 29.4 ± 5887.2 | 75.9 ± 40.8 | 90.7 ± 46.1 | 109 ± 48.2 | — | — | — | — |
| Cycle 1 Day 15 | 12.2 ± 1626.9 | 25.4 ± 29.8 | 28.9 ± 48.6 | 34.4 ± 37.3 | — | — | — | — |
| Cycle 2 Day 1: Pre-dose | 3.21 ± 546.5 | 12.4 ± 47.9 | 8.75 ± 77.7 | 16.6 ± 25.6 | 4.72 ± 159.8 | 12.7 ± 120.5 | 9.05 ± 74.4 | 13.1 ± 45.2 |
| Cycle 2 Day 1: 30 min Post Dose | 685 ± 22.0 | 683 ± 20.1 | 803 ± 20.1 | 834 ± 13.5 | — | — | — | — |
| Cycle 4 Day 1: Pre-dose | 12.2 ± 26.1 | 21.1 ± 46.7 | 15.3 ± 61.9 | 26.2 ± 22.1 | 11.2 ± 109.3 | 20.7 ± 46.4 | 15.2 ± 30.5 | 19.6 ± 30.5 |
| Cycle 4 Day 1: 30 min Post Dose | 748 ± 23.4 | 754 ± 14.4 | 734 ± 22.0 | 716 ± 13.7 | 689 ± 20.9 | 645 ± 21.4 | 829 ± 20.3 | 709 ± 10.1 |
| Unscheduled Visit | — | — | — | — | — | 41.1 ± 49.4 | 53.0 ± 58.0 | — |
| Unscheduled Visit: Pre-dose | — | — | — | — | 1.21 ± NA | 0.180 ± NA | — | — |
| Unscheduled Visit: 30 min Post Dose | — | — | — | — | — | 915 ± NA | — | — |
| Study Treatment Completion | — | — | 18.7 ± NA | — | 10.7 ± 181.7 | 14.2 ± 95.7 | 14.9 ± 69.4 | 12.3 ± 109.4 |
PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
| ng/mL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Cycle 1 Day 2: Post Dose | 653 ± 237 |
| Cycle 2 Day 1: Pre-dose | 14.6 ± 8.66 |
| Cycle 2 Day 1: Post Dose | 667 ± 155 |
| Cycle 4 Day 1: Pre-dose | 23.2 ± 8.59 |
| Cycle 4 Day 1: Post Dose | 659 ± 156 |
PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
| grams per milliliters (g/mL) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2: Pre-dose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 2: 30 min Post Dose | 33.2 ± 28.4 | 36.6 ± 25.4 | 37.5 ± 29.1 | 34.3 ± 20.3 | 35.4 ± 27.7 | 34.6 ± 26.2 | 32.4 ± 22.8 | 38.3 ± 20.3 |
| Cycle 1 Day 8 | 3.43 ± 4393.4 | 9.01 ± 43.7 | 10.2 ± 39.3 | 10.0 ± 31.9 | — | — | — | — |
| Cycle 1 Day 15 | 1.83 ± 1784.3 | 4.26 ± 35.3 | 4.61 ± 40.6 | 5.22 ± 28.4 | — | — | — | — |
| Cycle 2 Day 1: Pre-dose | 0.696 ± 941.2 | 2.31 ± 54.2 | 2.20 ± 76.1 | 3.70 ± 27.4 | 1.23 ± 203.1 | 2.48 ± 137.6 | 2.20 ± 100.6 | 2.83 ± 41.8 |
| Cycle 2 Day 1: 30 min Post Dose | 35.8 ± 25.9 | 39.5 ± 28.3 | 43.4 ± 31.1 | 42.2 ± 22.9 | — | — | — | — |
| Cycle 4 Day 1: Pre-dose | 3.44 ± 30.5 | 5.03 ± 59.0 | 4.61 ± 62.2 | 6.26 ± 18.3 | 3.61 ± 97.8 | 5.72 ± 39.9 | 4.82 ± 20.8 | 5.03 ± 29.3 |
| Cycle 4 Day 1: 30 min Post Dose | 40.2 ± 27.2 | 44.6 ± 11.0 | 43.0 ± 25.8 | 47.1 ± 24.2 | 44.8 ± 24.3 | 40.6 ± 20.6 | 55.0 ± 21.3 | 37.5 ± 11.6 |
| Follow up on Month 3, Day 1 | 0.164 ± 51.9 | 0.771 ± 193.4 | 0.910 ± 82.8 | 0.394 ± 27.1 | 0.265 ± 209.9 | 0.316 ± 266.2 | 0.489 ± 174.2 | 0.543 ± 126.7 |
| Follow up on Month 6, Day 1 | 0.0250 ± 0.0 | 0.0788 ± 230.0 | 0.219 ± 96.6 | 0.104 ± 18.5 | 0.0539 ± 145.7 | 0.0564 ± 195.7 | 0.0920 ± 123.5 | 0.150 ± 206.6 |
| Follow up on Month 12, Day 1 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | 0.0298 ± 35.9 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | 0.0301 ± 60.6 | 0.0250 ± 0.0 | 0.0250 ± 0.0 |
| Follow up on Month 18, Day 1 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | — | 0.0250 ± 0.0 | 0.0250 ± 0.0 |
| Follow up on Month 24, Day 1 | 0.0250 ± 0.0 | 0.0250 ± 0.0 | 0.0250 ± NA | 0.0250 ± NA | — | — | — | 0.0250 ± NA |
| Unscheduled Visit | 0.0250 ± 0.0 | 0.0250 ± 0.0 | — | 0.0250 ± NA | — | 1.65 ± 5419.8 | 1.23 ± 30267.8 | — |
| Unscheduled Visit: Pre-dose | — | — | — | — | 0.279 ± NA | 0.0250 ± NA | — | — |
| Unscheduled Visit: 30 min Post Dose | — | — | — | — | — | 42.0 ± NA | — | — |
| Study Treatment Completion Visit | — | — | 5.34 ± NA | — | 3.34 ± 180.5 | 4.33 ± 69.4 | 4.57 ± 57.2 | 3.23 ± 79.3 |
PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
| ng/mL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Cycle 1 Day 2: Post Dose | 33.9 ± 11.7 |
| Cycle 2 Day 1: Pre-dose | 3.27 ± 4.37 |
| Cycle 2 Day 1: Post Dose | 36.0 ± 8.71 |
| Cycle 4 Day 1: Pre-dose | 5.41 ± 1.79 |
| Cycle 4 Day 1: Post Dose | 39.2 ± 7.30 |
PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
| ng/mL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2: Pre-dose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 2: 30 min Post Dose | 0.726 ± 297.5 | 0.234 ± 80.2 | 0.397 ± 67.7 | 0.327 ± 41.4 | 0.402 ± 80.2 | 0.315 ± 105.3 | 0.243 ± 101.8 | 0.456 ± 103.1 |
| Cycle 1 Day 8 | 1.48 ± 100.8 | 1.84 ± 78.4 | 1.96 ± 51.5 | 2.34 ± 21.4 | — | — | — | — |
| Cycle 1 Day 15 | 0.311 ± 93.8 | 0.531 ± 88.5 | 0.705 ± 60.0 | 0.688 ± 19.5 | — | — | — | — |
| Cycle 2 Day 1: Pre-dose | 0.0264 ± 70.8 | 0.158 ± 79.4 | 0.0512 ± 129.3 | 0.150 ± 44.4 | 0.0373 ± 81.5 | 0.159 ± 80.9 | 0.0451 ± 76.9 | 0.186 ± 86.8 |
| Cycle 2 Day 1: 30 min Post Dose | 0.185 ± 54.2 | 0.263 ± 72.7 | 0.231 ± 53.5 | 0.345 ± 31.9 | — | — | — | — |
| Cycle 4 Day 1: Pre-dose | 0.0414 ± 102.9 | 0.133 ± 72.6 | 0.0511 ± 68.3 | 0.150 ± 44.3 | 0.0554 ± 77.3 | 0.158 ± 58.2 | 0.0481 ± 83.2 | 0.141 ± 102.3 |
| Cycle 4 Day 1: 30 min Post Dose | 0.234 ± 35.0 | 0.266 ± 27.0 | 0.167 ± 39.2 | 0.257 ± 32.3 | 0.198 ± 32.0 | 0.316 ± 38.9 | 0.195 ± 38.1 | 0.283 ± 56.9 |
| Unscheduled Visit | — | — | — | — | — | — | 0.738 ± 64.6 | — |
| Unscheduled Visit: Pre-dose | — | — | — | — | 0.0180 ± NA | 0.0180 ± NA | — | — |
| Unscheduled Visit: 30 min Post Dose | — | — | — | — | — | 0.114 ± NA | — | — |
| Study Treatment Completion | — | — | 0.0595 ± NA | — | 0.0506 ± 113.0 | 0.0749 ± 165.9 | 0.0682 ± 110.4 | 0.150 ± 179.4 |
PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
| ng/mL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|
| Cycle 1 Day 2: Post Dose | 0.590 ± 1.08 |
| Cycle 2 Day 1: Pre-dose | 0.229 ± 0.248 |
| Cycle 2 Day 1: Post Dose | 0.316 ± 0.213 |
| Cycle 4 Day 1: Pre-dose | 0.186 ± 0.118 |
| Cycle 4 Day 1: Post Dose | 0.256 ± 0.118 |
Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).
| ng/mL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2: Pre-dose | — | — | — | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 2: 5 min Post Dose | — | — | — | — | 2130 ± 665.6 | 2810 ± 222.7 | 2740 ± 550.9 | 1700 ± 1865.5 | 3090 ± 68.3 | 3790 ± 119.4 |
| Cycle 1 Day 2: 1h Post Dose | — | — | — | — | 456 ± 167.8 | 353 ± 187.9 | 518 ± 154.2 | 451 ± 380.2 | 478 ± 111.4 | 639 ± 165.6 |
| Cycle 1 Day 2: 2h Post Dose | — | — | — | — | 84.4 ± 173.5 | 55.1 ± 236.5 | 93.8 ± 250.5 | 101 ± 375.8 | 62.8 ± 104.3 | 128 ± 196.7 |
| Cycle 1 Day 2: 3h Post Dose | — | — | — | — | 20.5 ± 220.1 | 12.7 ± 246.4 | 23.5 ± 461.0 | 21.5 ± 509.9 | 12.4 ± 132.0 | 28.2 ± 287.4 |
| Cycle 1 Day 2: 4h Post Dose | — | — | — | — | 7.60 ± 278.5 | 4.58 ± 268.4 | 8.11 ± 724.8 | 8.08 ± 615.9 | 3.30 ± 147.2 | 6.18 ± 131.0 |
Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).
| ng/mL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL |
|---|---|---|---|---|---|---|
| Cycle 1 Days 1: Pre-dose | — | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Days 1: 30 min Post Dose | — | — | 182 ± 27.2 | 202 ± 24.5 | 188 ± 19.9 | 180 ± 18.0 |
| Cycle 2 Days 1: Pre-dose | — | — | 22.8 ± 79.2 | 20.2 ± 145.9 | 34.9 ± 89.9 | 34.6 ± 69.7 |
| Cycle 4 Days 1: Pre-dose | — | — | 65.1 ± 46.5 | 62.3 ± 42.7 | 74.7 ± 50.9 | 83.3 ± 49.1 |
| Unscheduled: Pre-dose | — | — | 30.6 ± 118.0 | — | 298 ± NA | 2.00 ± NA |
| Unscheduled: 30 min Post Dose | — | — | — | — | — | 165 ± NA |
Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
| g/mL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|---|---|
| Cycle 1 Day 1: Pre-dose | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 1: 30 min Post Dose | — | — | 341 ± 22.1 | 221 ± 105.5 |
| Cycle 2 Day 1: Pre-dose | 283 ± 38.4 | 412 ± 40.8 | 301 ± 39.3 | 349 ± 58.0 |
| Cycle 4 Day 1: Pre-dose | 293 ± 53.8 | 359 ± 28.9 | 291 ± 37.9 | 290 ± 36.4 |
| Cycle 4 Day 1: 30 min Post Dose | — | — | 701 ± 27.4 | 642 ± 29.5 |
| Follow up on Month 3, Day 1 | 67.7 ± 47.8 | 28.8 ± 17.0 | 38.5 ± 167.8 | 55.1 ± 119.9 |
| Follow up on Month 6, Day 1 | 11.5 ± 56.6 | 5.38 ± 12.4 | 7.64 ± 412.2 | 15.8 ± 137.6 |
| Follow up on Month 12, Day 1 | 0.237 ± 717.6 | 0.389 ± 119.3 | 0.162 ± 569.7 | 0.732 ± 18.7 |
| Follow up on Month 18, Day 1 | 0.00978 ± 1188.5 | 0.0107 ± 170.5 | 0.00842 ± 347.4 | 0.0460 ± 86.9 |
| Follow up on Month 24, Day 1 | 0.00203 ± NA | 0.00203 ± NA | — | 0.00203 ± NA |
| Unscheduled | — | 3.09 ± NA | 20.8 ± NA | — |
| Unscheduled Visit: Pre-dose | — | — | — | 0.0626 ± NA |
| Unscheduled Visit: 30 min Post Dose | — | — | — | 349 ± NA |
| Study Treatment Completion Visit | 367 ± NA | — | 242 ± 52.7 | 232 ± 46.2 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| ng/mL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL |
|---|---|---|
| acMMAE: Cycle 1 | 676 ± 176 | 634 ± 158 |
| acMMAE: Cycle 2 | 697 ± 129 | 694 ± 138 |
| acMMAE: Cycle 4 | 763 ± 159 | 759 ± 107 |
| Total Ab: Cycle 1 | 34.3 ± 8.57 | 37.6 ± 9.42 |
| Total Ab: Cycle 2 | 36.6 ± 8.00 | 40.6 ± 9.46 |
| Total Ab: Cycle 4 | 41.3 ± 9.98 | 44.8 ± 5.06 |
| Unconjugated MMAE: Cycle 1 | 3.31 ± 4.00 | 2.21 ± 1.34 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| ng/mL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL |
|---|---|---|
| acMMAE: Cycle 1 | 738 ± 165 | 725 ± 104 |
| acMMAE: Cycle 2 | 816 ± 168 | 841 ± 115 |
| acMMAE: Cycle 4 | 749 ± 158 | 721 ± 97.7 |
| Total Ab: Cycle 1 | 38.7 ± 9.84 | 34.9 ± 7.52 |
| Total Ab: Cycle 2 | 45.0 ± 12.1 | 43.1 ± 9.52 |
| Total Ab: Cycle 4 | 44.2 ± 11.2 | 48.2 ± 12.5 |
| Unconjugated MMAE: Cycle 1 | 2.17 ± 1.08 | 2.39 ± 0.492 |
PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.
| ng/mL | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL |
|---|---|---|
| acMMAE: Cycle 1 | 622 ± 194 | 661 ± 149 |
| acMMAE: Cycle 4 | 703 ± 150 | 659 ± 135 |
| Total Ab: Cycle 1 | 36.7 ± 9.54 | 35.7 ± 8.50 |
| Total Ab: Cycle 4 | 46.1 ± 11.4 | 41.4 ± 8.29 |
| Bendamustine: Cycle 1 | 3.57 ± 2.06 | 4.23 ± 2.26 |
| Rituximab: Cycle 1 | 188 ± 49.2 | 191 ± 35.9 |
| ug/mL | Arm B (Phase II Randomization): BR in FL | Arm D (Phase II Randomization): BR in DLBCL |
|---|---|---|
| Bendamustine | 3.21 ± 2.09 | 3.85 ± 2.91 |
| Rituximab | 207 ± 50.1 | 183 ± 33.6 |
PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.
| ug/mL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|
| acMMAE: Cycle 1 | 692 ± 230 | 703 ± 211 |
| acMMAE: Cycle 4 | 845 ± 165 | 713 ± 70.6 |
| Total Ab: Cycle 1 | 33.3 ± 8.04 | 39.0 ± 7.63 |
| Total Ab: Cycle 4 | 56.1 ± 11.2 | 37.8 ± 4.51 |
| Bendamustine: Cycle 1 | 3.30 ± 1.58 | 5.47 ± 4.30 |
| Obinutuzumab: Cycle 1 | 349 ± 72.8 | 274 ± 118 |
| Obinutuzumab: Cycle 4 | 727 ± 217 | 666 ± 190 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
No measurements were reported for this outcome.
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day\*micrograms per milliliter \[day\*ug/mL\]).
| day*ug/mL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL |
|---|---|---|
| acMMAE | 2830 ± 12.1 | 2110 ± 28.4 |
| Total Ab | 298 ± 4.9 | 214 ± 35.9 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| day*ug/mL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL |
|---|---|---|
| acMMAE | 2600 ± 34.4 | 2650 ± 16.4 |
| Total Ab | 267 ± 30.2 | 252 ± 21.6 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| h*ug/mL | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL |
|---|---|---|
| Bendamustine | 3.29 ± 73.3 | 3.62 ± 78.5 |
| h*ug/mL | Arm B (Phase II Randomization): BR in FL | Arm D (Phase II Randomization): BR in DLBCL |
|---|---|---|
| Bendamustine | 2.86 ± 67.3 | 3.43 ± 97.4 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| h*ug/mL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|
| Bendamustine | 2.88 ± 28.9 | 4.10 ± 67.4 |
PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.
No measurements were reported for this outcome.
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| mL/day/kg | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL |
|---|---|---|
| acMMAE | 11.3 ± 12.9 | 15.2 ± 27.9 |
| Total Ab | 6.05 ± 4.7 | 8.48 ± 35.2 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| mL/day/kg | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL |
|---|---|---|
| acMMAE | 12.3 ± 34.9 | 12.1 ± 17.0 |
| Total Ab | 6.76 ± 30.6 | 7.17 ± 22.2 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| Liters per hour (L/h) | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL |
|---|---|---|
| Bendamustine | 47.9 ± 60.8 | 42.6 ± 66.4 |
| L/h | Arm B (Phase II Randomization): BR in FL | Arm D (Phase II Randomization): BR in DLBCL |
|---|---|---|
| Bendamustine | 54.4 ± 60.9 | 46.4 ± 93.9 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| L/h | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|
| Bendamustine | 61.3 ± 33.4 | 39.9 ± 76.1 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
No measurements were reported for this outcome.
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| mL/kg | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL |
|---|---|---|
| acMMAE | 73.0 ± 22.3 | 82.7 ± 33.2 |
| Total Ab | 82.3 ± 9.1 | 76.6 ± 25.7 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| mL/kg | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL |
|---|---|---|
| acMMAE | 77.2 ± 38.8 | 64.7 ± 23.0 |
| Total Ab | 87.5 ± 38.5 | 87.9 ± 24.7 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| L | Arm A (Phase II Randomization): Pola+BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL |
|---|---|---|
| Bendamustine | 36.5 ± 86.4 | 34.3 ± 57.7 |
| L | Arm B (Phase II Randomization): BR in FL | Arm D (Phase II Randomization): BR in DLBCL |
|---|---|---|
| Bendamustine | 44.9 ± 69.6 | 33.2 ± 62.9 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
| L | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|
| Bendamustine | 51.2 ± 33.6 | 31.5 ± 68.1 |
PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
No measurements were reported for this outcome.
The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.
| Points on scale | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL |
|---|---|---|---|---|---|---|
| Baseline | 0.2 ± 0.3 | 0.5 ± 1.1 | 0.4 ± 0.6 | 0.6 ± 0.7 | 0.8 ± 1.6 | — |
| Week 1 | 0.3 ± 0.4 | — | — | — | 0.0 ± NA | — |
| Week 2 | 0.3 ± 0.4 | 0.5 ± 1.3 | 0.3 ± 0.4 | 1.0 ± 1.1 | 0.2 ± 0.2 | — |
| Week 3 | 0.2 ± 0.5 | 0.7 ± 1.5 | 0.1 ± 0.1 | 0.9 ± 0.1 | 0.0 ± 0.1 | — |
| Week 4 | 0.1 ± 0.2 | 0.8 ± 1.8 | 0.3 ± 0.3 | 0.7 ± 0.8 | 0.2 ± 0.4 | — |
| Week 5 | 0.2 ± 0.3 | 0.6 ± 1.4 | 0.3 ± 0.5 | 0.6 ± 0.6 | 0.1 ± 0.2 | — |
| Week 6 | 0.2 ± 0.4 | 0.8 ± 1.8 | 0.3 ± 0.5 | 0.7 ± 1.0 | 0.1 ± 0.3 | — |
| Week 7 | 0.3 ± 0.4 | 0.9 ± 1.9 | 0.2 ± 0.3 | 0.4 ± 0.6 | 0.0 ± 0.1 | — |
| Week 8 | 0.3 ± 0.4 | 0.8 ± 1.8 | 0.2 ± 0.5 | 0.6 ± 0.9 | 0.2 ± 0.4 | — |
| Week 9 | 0.4 ± 0.9 | 0.5 ± 0.9 | 0.2 ± 0.3 | 0.5 ± 0.7 | 0.1 ± 0.3 | — |
| Week 10 | 0.5 ± 0.9 | 0.4 ± 0.8 | 0.1 ± 0.1 | 0.2 ± 0.4 | 0.1 ± 0.2 | — |
| Week 11 | 0.5 ± 1.0 | 0.5 ± 0.9 | 0.2 ± 0.2 | 0.4 ± 0.6 | 0.1 ± 0.1 | — |
| Week 12 | 0.5 ± 1.4 | 0.9 ± 2.0 | 0.3 ± 0.4 | 0.3 ± 0.6 | 0.2 ± 0.2 | — |
| Week 13 | 0.7 ± 1.2 | 0.6 ± 1.6 | 0.3 ± 0.4 | 0.2 ± 0.4 | 0.3 ± 0.4 | — |
| Week 14 | 0.6 ± 1.2 | 0.7 ± 1.8 | 0.3 ± 0.3 | 0.4 ± 0.6 | 0.2 ± 0.4 | — |
| Week 15 | 0.2 ± 0.3 | 0.7 ± 1.7 | 0.4 ± 0.5 | 0.4 ± 0.4 | 0.9 ± 1.6 | — |
| Week 16 | 0.4 ± 0.5 | 0.8 ± 1.8 | 0.4 ± 0.4 | 0.4 ± 0.5 | 0.3 ± 0.7 | — |
| Week 17 | 0.2 ± 0.3 | 0.8 ± 1.8 | 0.5 ± 0.7 | 0.4 ± 0.6 | 0.3 ± 0.5 | — |
| Week 18 | 0.2 ± 0.3 | 0.7 ± 1.8 | 0.3 ± 0.4 | 0.1 ± 0.1 | 0.3 ± 0.5 | — |
| Week 19 | 0.2 ± 0.3 | 0.8 ± 2.0 | 0.4 ± 0.7 | 0.5 ± 0.8 | 0.3 ± 0.5 | — |
| Week 20 | 0.0 ± 0.2 | 0.8 ± 1.9 | 0.6 ± 0.8 | 0.1 ± 0.1 | 0.3 ± 0.4 | — |
| Week 21 | 0.3 ± 0.3 | 0.9 ± 1.9 | 0.5 ± 0.5 | 0.1 ± 0.1 | 0.3 ± 0.3 | — |
| Week 22 | 0.2 ± 0.2 | 0.8 ± 2.0 | 0.9 ± 1.5 | 0.0 ± NA | 0.5 ± 0.6 | — |
| Week 23 | 0.2 ± 0.3 | 0.8 ± 2.2 | 0.6 ± 0.7 | 0.0 ± NA | 0.5 ± 0.6 | — |
| Week 24 | 0.4 ± 0.6 | 1.0 ± 2.3 | 0.5 ± 0.7 | 0.0 ± 0.1 | 0.3 ± 0.3 | — |
| Week 25 | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.3 ± 0.4 | 0.0 ± NA | 0.1 ± 0.1 | — |
| Week 26 | 0.6 ± 0.8 | 3.3 ± 4.4 | 0.4 ± 0.6 | 0.0 ± NA | — | — |
| Week 27 | 0.3 ± 0.3 | 1.1 ± 2.5 | 0.5 ± 0.6 | 0.1 ± 0.1 | 0.4 ± 0.4 | — |
| Week 28 | 0.5 ± 0.6 | 1.2 ± 2.6 | 0.5 ± 0.7 | 0.0 ± NA | 0.1 ± 0.2 | — |
| Week 29 | 0.2 ± 0.2 | 0.8 ± 2.1 | 0.7 ± 0.7 | 0.0 ± NA | 0.1 ± 0.2 | — |
| Week 30 | 0.7 ± 1.1 | 0.7 ± 1.9 | 0.8 ± 0.8 | 0.0 ± NA | 0.1 ± 0.1 | — |
| Week 31 | 0.3 ± 0.3 | 0.0 ± 0.1 | 1.3 ± 0.9 | 0.0 ± NA | 0.1 ± 0.1 | — |
| Week 32 | 0.4 ± 0.4 | 0.1 ± 0.1 | 1.0 ± 0.9 | — | 0.2 ± 0.3 | — |
| Week 33 | 0.3 ± 0.3 | 0.1 ± 0.2 | 1.0 ± 1.0 | — | 0.2 ± 0.2 | — |
| Week 34 | 0.2 ± 0.2 | 1.3 ± 2.4 | 0.8 ± 0.5 | — | 0.2 ± 0.3 | — |
| Week 35 | 0.3 ± 0.3 | 0.0 ± NA | 1.2 ± 0.7 | 0.6 ± 0.9 | 0.4 ± NA | — |
| Week 36 | 0.5 ± 0.3 | 0.2 ± 0.3 | 1.2 ± 0.6 | — | 0.1 ± 0.2 | — |
| Week 37 | 0.4 ± 0.4 | 0.1 ± 0.1 | 1.1 ± 0.8 | — | 0.2 ± 0.3 | — |
| Week 38 | 0.4 ± 0.4 | 0.1 ± NA | 1.5 ± 0.4 | — | 0.3 ± NA | — |
| Week 39 | 0.7 ± 0.9 | 0.0 ± NA | 1.5 ± 0.5 | 0.0 ± NA | 0.3 ± NA | — |
| Week 40 | 0.5 ± 0.4 | 0.0 ± NA | 0.9 ± 0.4 | — | 0.1 ± 0.2 | — |
| Week 41 | 0.6 ± 0.6 | 0.7 ± 1.6 | 1.4 ± 1.2 | — | 0.3 ± 0.4 | — |
| Week 42 | 0.5 ± 0.5 | 0.0 ± NA | 0.3 ± NA | — | 0.5 ± NA | — |
| Week 43 | 0.3 ± 0.4 | 0.0 ± NA | 0.6 ± NA | 0.0 ± NA | 0.4 ± NA | — |
| Week 44 | 1.6 ± NA | 0.0 ± NA | 0.2 ± 0.3 | — | 0.7 ± NA | — |
| Week 45 | 0.8 ± 0.7 | 0.1 ± 0.2 | 1.0 ± 1.2 | — | 0.3 ± 0.4 | — |
| Week 46 | 1.1 ± 0.7 | 0.1 ± NA | 0.2 ± NA | — | 0.5 ± NA | — |
| Week 47 | 0.4 ± 0.6 | 0.0 ± NA | 0.1 ± NA | — | 0.8 ± NA | — |
| Week 48 | — | 0.8 ± 0.9 | 0.2 ± 0.2 | — | 0.6 ± NA | — |
| Week 49 | 0.6 ± 0.6 | 0.0 ± 0.0 | 1.1 ± 1.4 | — | 0.3 ± 0.4 | — |
| Week 50 | 1.0 ± 0.2 | 0.1 ± NA | 0.2 ± NA | — | 0.5 ± NA | — |
| Week 51 | 0.1 ± 0.2 | 0.0 ± NA | 0.2 ± NA | — | 0.5 ± NA | — |
| Week 52 | 0.4 ± NA | 0.4 ± 0.5 | 0.2 ± NA | — | 0.5 ± NA | — |
| Week 53 | 0.2 ± NA | 0.7 ± 1.5 | 0.2 ± NA | — | 0.2 ± 0.3 | — |
| Week 54 | 0.8 ± 0.6 | 0.0 ± NA | 0.2 ± NA | — | 0.5 ± NA | — |
| Week 55 | 0.3 ± 0.5 | 0.2 ± NA | 0.2 ± NA | — | 0.5 ± NA | — |
| Week 56 | 0.6 ± 0.3 | 0.2 ± NA | 0.0 ± 0.1 | — | — | — |
| Week 57 | 0.3 ± NA | 0.0 ± 0.0 | 1.5 ± 2.1 | — | 0.2 ± 0.3 | — |
| Week 58 | 0.7 ± 0.6 | — | 0.0 ± NA | — | 0.6 ± NA | — |
| Week 59 | 0.0 ± 0.1 | 0.0 ± NA | 0.0 ± NA | — | 0.6 ± NA | — |
| Week 60 | 0.4 ± NA | — | 0.0 ± NA | — | — | — |
| Week 61 | 0.4 ± 0.3 | 0.3 ± 0.5 | 1.5 ± 2.1 | — | 0.3 ± 0.5 | — |
| Week 62 | 0.7 ± 1.0 | — | 0.0 ± NA | — | 0.6 ± NA | — |
| Week 63 | 0.4 ± 0.7 | 0.0 ± NA | 0.0 ± NA | — | 0.8 ± NA | — |
| Week 64 | 0.4 ± NA | 1.1 ± NA | 0.1 ± 0.2 | — | 0.7 ± NA | — |
| Week 65 | 0.2 ± 0.0 | 0.0 ± 0.0 | 0.8 ± 1.3 | — | 0.0 ± NA | — |
| Week 66 | 0.6 ± 0.7 | — | 0.0 ± NA | — | 0.8 ± NA | — |
| Week 67 | 0.2 ± 0.3 | — | 0.0 ± NA | — | 0.9 ± NA | — |
| Week 68 | — | — | 0.0 ± NA | — | 1.2 ± NA | — |
| Week 69 | 0.2 ± NA | 0.3 ± 0.5 | 1.5 ± 2.1 | — | 0.0 ± NA | — |
| Week 70 | 0.7 ± 1.0 | — | 0.0 ± NA | — | 1.0 ± NA | — |
| Week 71 | 0.1 ± 0.1 | — | 0.0 ± NA | — | 0.8 ± NA | — |
| Week 72 | — | 1.2 ± NA | 0.0 ± NA | — | 0.9 ± NA | — |
| Week 73 | 0.4 ± 0.3 | 0.0 ± 0.0 | 1.3 ± 1.8 | — | 0.0 ± NA | — |
| Week 74 | 1.3 ± 0.7 | — | 0.0 ± NA | — | 0.8 ± NA | — |
| Week 75 | 0.2 ± 0.0 | — | 0.0 ± NA | — | 1.1 ± NA | — |
| Week 76 | — | — | 0.7 ± NA | — | 0.6 ± NA | — |
| Week 77 | — | — | 1.5 ± NA | — | 0.9 ± NA | — |
| Week 78 | 0.7 ± NA | — | 1.4 ± NA | — | — | — |
| Week 79 | — | — | 1.4 ± NA | — | 0.8 ± NA | — |
| Week 80 | 0.0 ± NA | — | 1.1 ± NA | — | 0.8 ± NA | — |
| Week 81 | — | — | 0.6 ± NA | — | — | — |
| Week 82 | — | — | 0.6 ± NA | — | — | — |
| Week 83 | — | — | 0.6 ± NA | — | 0.8 ± NA | — |
| Week 84 | 0.0 ± NA | — | 0.6 ± NA | — | — | — |
| Week 85 | — | — | 0.6 ± NA | — | 0.6 ± NA | — |
| Week 86 | 0.6 ± NA | — | 0.6 ± NA | — | 0.6 ± NA | — |
| Week 89 | — | — | — | — | 0.7 ± NA | — |
| Week 90 | 0.7 ± NA | — | — | — | 0.7 ± NA | — |
| Week 91 | — | — | — | — | 0.7 ± NA | — |
| Week 92 | — | — | — | — | 0.7 ± NA | — |
| Week 93 | — | — | — | — | 0.7 ± NA | — |
| Week 94 | — | — | 0.0 ± NA | — | 0.7 ± NA | — |
| Week 95 | — | — | 0.5 ± NA | — | 0.7 ± NA | — |
| Week 96 | — | — | 0.0 ± NA | — | 0.8 ± NA | — |
| Week 97 | — | — | — | — | 0.7 ± NA | — |
| Week 98 | — | — | 0.0 ± NA | — | 0.7 ± NA | — |
| Week 99 | — | — | 0.1 ± NA | — | 0.7 ± NA | — |
| Week 100 | — | — | 0.3 ± NA | — | 0.7 ± NA | — |
| Week 101 | — | — | — | — | 0.7 ± NA | — |
| Week 102 | — | — | 0.2 ± NA | — | 0.7 ± NA | — |
| Week 103 | — | — | 0.3 ± NA | — | 0.7 ± NA | — |
| Week 104 | — | — | 0.2 ± NA | — | 0.7 ± NA | — |
| Week 105 | — | — | 0.1 ± NA | — | 0.8 ± NA | — |
| Week 107 | — | — | — | — | 0.7 ± NA | — |
| Week 108 | — | — | — | — | 0.7 ± NA | — |
| End of Treatment | 0.4 ± 0.6 | 0.6 ± 1.8 | 0.5 ± 0.8 | 0.8 ± 1.0 | 0.1 ± 0.2 | — |
Collected over From Baseline up to study completion/discontinuation (up to approximately 84 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | 4/6 (66.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Arm A (Phase II Randomization): Pola+BR in FL | 16/39 (41%) | 25/38 (65.8%) | 38/38 (100%) |
| Arm B (Phase II Randomization): BR in FL | 11/41 (26.8%) | 12/41 (29.3%) | 39/41 (95.1%) |
| Arm C (Phase II Randomization): Pola+BR in DLBCL | 26/40 (65%) | 24/39 (61.5%) | 36/39 (92.3%) |
| Arm D (Phase II Randomization): BR in DLBCL | 30/40 (75%) | 27/39 (69.2%) | 37/39 (94.9%) |
| Arm E (Phase II Expansion): Pola+BG in FL | 3/20 (15%) | 8/20 (40%) | 20/20 (100%) |
| Arm F (Phase II Expansion): Pola+BG in DLBCL | 18/21 (85.7%) | 13/20 (65%) | 19/20 (95%) |
| Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | 65/106 (61.3%) | 57/106 (53.8%) | 103/106 (97.2%) |
| Event | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 0/6 | 1/6 | 0/6 | 2/6 | 7/38 | 1/41 | 4/39 | 4/39 | 0/20 | 0/20 | 6/106 |
| SEPSISInfections and infestations | 0/6 | 0/6 | 2/6 | 0/6 | 1/38 | 1/41 | 2/39 | 2/39 | 0/20 | 1/20 | 7/106 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/6 | 0/6 | 0/6 | 1/6 | 6/38 | 1/41 | 4/39 | 4/39 | 2/20 | 2/20 | 9/106 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/38 | 0/41 | 1/39 | 0/39 | 0/20 | 1/20 | 2/106 |
| NAUSEAGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/38 | 0/41 | 0/39 | 0/39 | 0/20 | 0/20 | 1/106 |
| PYREXIAGeneral disorders | 0/6 | 1/6 | 0/6 | 1/6 | 2/38 | 1/41 | 0/39 | 5/39 | 0/20 | 2/20 | 7/106 |
| HEPATIC CIRRHOSISHepatobiliary disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/38 | 0/41 | 0/39 | 0/39 | 0/20 | 0/20 | 0/106 |
| CLOSTRIDIAL SEPSISInfections and infestations | 0/6 | 1/6 | 0/6 | 0/6 | 0/38 | 0/41 | 0/39 | 0/39 | 0/20 | 0/20 | 0/106 |
| INFECTED LYMPHOCELEInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/38 | 0/41 | 0/39 | 0/39 | 0/20 | 0/20 | 0/106 |
| LARGE INTESTINE INFECTIONInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 | 0/38 | 0/41 | 0/39 | 0/39 | 0/20 | 0/20 | 0/106 |
| Event | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 3/6 | 3/6 | 5/6 | 3/6 | 22/38 | 13/41 | 16/39 | 12/39 | 11/20 | 11/20 | 34/106 |
| VOMITINGGastrointestinal disorders | 2/6 | 1/6 | 5/6 | 1/6 | 7/38 | 8/41 | 5/39 | 7/39 | 8/20 | 8/20 | 17/106 |
| CONSTIPATIONGastrointestinal disorders | 3/6 | 1/6 | 4/6 | 2/6 | 10/38 | 8/41 | 8/39 | 7/39 | 7/20 | 9/20 | 20/106 |
| DIARRHOEAGastrointestinal disorders | 2/6 | 2/6 | 4/6 | 4/6 | 16/38 | 9/41 | 11/39 | 16/39 | 10/20 | 11/20 | 36/106 |
| FATIGUEGeneral disorders | 4/6 | 4/6 | 3/6 | 2/6 | 16/38 | 13/41 | 14/39 | 14/39 | 13/20 | 12/20 | 22/106 |
| NEUTROPENIABlood and lymphatic system disorders | 2/6 | 0/6 | 2/6 | 1/6 | 16/38 | 11/41 | 14/39 | 21/39 | 6/20 | 6/20 | 35/106 |
| CHILLSGeneral disorders | 1/6 | 1/6 | 3/6 | 2/6 | 0/38 | 3/41 | 3/39 | 4/39 | 2/20 | 5/20 | 2/106 |
| DECREASED APPETITEMetabolism and nutrition disorders | 3/6 | 2/6 | 2/6 | 3/6 | 10/38 | 5/41 | 8/39 | 10/39 | 6/20 | 8/20 | 27/106 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 1/6 | 3/6 | 2/6 | 2/6 | 5/38 | 4/41 | 3/39 | 4/39 | 3/20 | 5/20 | 15/106 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 1/6 | 2/6 | 1/6 | 3/6 | 4/38 | 1/41 | 4/39 | 1/39 | 4/20 | 1/20 | 13/106 |
Intent-to-treat (ITT) population included all participants who were randomized, whether or not the participants received the assigned treatment.
| Age, Continuous(years) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 68.0 (54 to 73) | 65.0 (58 to 79) | 63.5 (42 to 73) | 71.0 (53 to 84) | 65.0 (37 to 74) | 63.0 (39 to 80) | 67.0 (33 to 86) | 71.0 (30 to 84) | 60.5 (37 to 86) | 65.0 (26 to 86) | 70.0 (24 to 94) | 67.0 (24 to 94) |
| Sex: Female, Male(Participants) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 2 | 1 | 18 | 23 | 12 | 15 | 10 | 10 | 54 | 151 |
| Male | 2 | 4 | 4 | 5 | 21 | 18 | 28 | 25 | 10 | 11 | 52 | 180 |
| Race (NIH/OMB)(Participants) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 1 | 0 | 0 | 1 | 2 | 6 | 4 | 1 | 6 | 8 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 2 | 0 | 1 | 7 |
| White | 5 | 5 | 6 | 6 | 33 | 33 | 26 | 31 | 16 | 15 | 83 | 259 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 4 | 6 | 5 | 4 | 1 | 0 | 14 | 34 |
| Race/Ethnicity, Customized(Participants) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Arm A (Phase II Randomization): Pola+BR in FL | Arm B (Phase II Randomization): BR in FL | Arm C (Phase II Randomization): Pola+BR in DLBCL | Arm D (Phase II Randomization): BR in DLBCL | Arm E (Phase II Expansion): Pola+BG in FL | Arm F (Phase II Expansion): Pola+BG in DLBCL | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 1 | 3 | 2 | 3 | 14 |
| Not Hispanic or Latino | 6 | 6 | 6 | 6 | 34 | 34 | 35 | 36 | 16 | 19 | 87 | 285 |
| Not Stated | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 1 | 0 | 0 | 13 | 22 |
| Unknown | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 1 | 0 | 3 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in Oct 2021, 84 months.
Results were first posted in Nov 2022, 1 year after primary completion.
Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's 84 months is above that.
Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Polatuzumab vedotin · Rituximab